Avatar
Forbes @forbes.com 路 Jersey City, New Jersey 馃嚡馃嚜路 6d

#Neuropsychiatry #DrugDevelopment #MentalHealth

Link Preview
www.forbes.com
Startup Organotics Fast Tracks Personalized Brain Drug Trials
Psychiatric drug development has a sobering statistic: nearly 96% of neuropsychiatric drugs fail, including many aimed at autism, bipolar disorder, and schizophrenia.
Avatar
NASDAQ Stock Market @nasdaq.com 路 New York City 馃嚭馃嚫路 Jan 5

#Pharmaceuticals #ClinicalTrials #DrugDevelopment

Link Preview
www.nasdaq.com
Crinetics To Provide Update On PALSONIFY And Topline Results From Phase 2 Trial Of Atumelnant In CAH
(RTTNews) - Crinetics Pharmaceuticals, Inc. (CRNX) is scheduled to host a conference call to provide an update on its lead drug PALSONIFY's commercialisation and disclose topline results from the fourth cohort of its Phase 2 trial of Atumelnant in congenital adrenal hyperplasia or CAH, today.
Avatar
Seeking Alpha @seekingalpha.com 路 Jan 4

#Biotech #DrugDevelopment #Investing

Link Preview
seekingalpha.com
GH Research: GH001 Shows Robust Data Ahead Of FDA IND Decision (NASDAQ:GHRS)
A positive IND outcome could catalyze further upside, but current valuation reflects significant optimism already priced in.